A Randomized, Double-blind Trial of Oral Fecal Microbiota Transplantation versus Placebo for the Eradication of Vancomycin-resistant Enterococci Colonization from the Gut (VRE-FMT)
The VRE-FMT trial (pending NIH U01) will test a novel intervention, fecal microbiota transplant (FMT) in oral encapsulation, for eradication of vacomycin-resistant enterococci (VRE) colonization in asymptomatic VRE gut colonized patients in a randomized, double-blind, placebo-controlled trial.
| Principal Investigator DCC: | Nasia Safdar, MD, University of Wisconsin-Madison |
| Co-Investigator, DCC Director: | KyungMann Kim, PhD, University of Wisconsin-Madison |
| Target Enrollment: | 90 |
The VRE-FMT Data Coordinating Center (DCC) will be led by Professor Kim. He will provide expertise and support for the VRE-FMT trial with limited involvement in data management which will be done using REDCap.
| Active Projects | Pending Projects | Data Systems | Think Tanks |
Contact Us
KyungMann Kim, PhD
DCC Principal Investigator
kyungmann.kim@wisc.edu
608-265-6380
Kelly Miller, BS, CCRC
DCC Research Administrator
kamiller@biostat.wisc.edu
608-262-8141